CY1108577T1 - Συνθεση εξω-s-μεκαμυλαμινης - Google Patents
Συνθεση εξω-s-μεκαμυλαμινηςInfo
- Publication number
- CY1108577T1 CY1108577T1 CY20081101333T CY081101333T CY1108577T1 CY 1108577 T1 CY1108577 T1 CY 1108577T1 CY 20081101333 T CY20081101333 T CY 20081101333T CY 081101333 T CY081101333 T CY 081101333T CY 1108577 T1 CY1108577 T1 CY 1108577T1
- Authority
- CY
- Cyprus
- Prior art keywords
- exo
- mecamylamine
- pharmaceutically acceptable
- disorder
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Μία φαρμακευτική σύνθεση περιλαμβάνει μία θεραπευτικά αποτελεσματική ποσότητα εξω-S-μεκαμυλαμίνης ή ενός φαρμακευτικά αποδεκτού άλατος της, αισθητά απαλλαγμένης εξω-R-μεκαμυλαμίνης σε συνδυασμό με ένα φαρμακευτικά αποδεκτό φορέα. Κατά προτίμηση η ποσότητα είναι περίπου 0,5 mg έως περίπου 20 mg. Οι ιατρικές καταστάσεις αντιμετωπίζονται δια χορηγήσεως μίας θεραπευτικά αποτελεσματικής ποσότητος εξω-S-μεκαμυλαμίνης ή ενός φαρμακευτικά αποδεκτού άλατος της, αισθητά απαλλαγμένης εξω-R-μεκαμυλαμίνης, όπου η εν λόγω ποσότητα είναι επαρκής για τη βελτίωση της ιατρικής καταστάσεως. Οι ιατρικές καταστάσεις περιλαμβάνουν αλλά δεν περιορίζονται σ' αυτές τον εθισμό σε ουσίες (οι οποίες περιλαμβάνουν νικοτίνη, κοκαΐνη, οινόπνευμα, αμφεταμίνη, οπιούχα, άλλα ψυχοδιεγερτικά και ένα συνδυασμό τους), την υποβοήθηση της διακοπής του καπνίσματος, την αγωγή της αυξήσεως του βάρους που συνδέεται με τη διακοπή του καπνίσματος, την υπέρταση, την υπερτασική κρίση, το σύνδρομο Tourette και άλλους τρόμους, τον καρκίνο (όπως το μικροκυτταρικό καρκίνο του πνευμόνος), την αθηρογόνο εικόνα, τις νευροψυχιατρικές διαταραχές (όπως η διπολική διαταραχή, μία διαταραχή άγχους, η σχιζοφρένια, μία διαταραχή αποπληξίας, η νόσος του Parkinson και η διαταραχή ελλείψεως προσοχής υπερδραστηριότητος), το σύνδρομο χρόνιας κοπώσεως, τη νόσο του Crohn, την αυτόνομη δυσκαμψία και τις σπασμογενείς εντερικές διαταραχές.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11253498P | 1998-12-16 | 1998-12-16 | |
EP05024899A EP1634498B1 (en) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylamine formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108577T1 true CY1108577T1 (el) | 2014-04-09 |
Family
ID=22344414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101333T CY1108577T1 (el) | 1998-12-16 | 2008-11-19 | Συνθεση εξω-s-μεκαμυλαμινης |
Country Status (12)
Country | Link |
---|---|
US (1) | US20020016370A1 (el) |
EP (3) | EP1139743B1 (el) |
JP (5) | JP2002532393A (el) |
AT (2) | ATE320711T1 (el) |
AU (2) | AU2368600A (el) |
CA (2) | CA2393437C (el) |
CY (1) | CY1108577T1 (el) |
DE (2) | DE69930552T2 (el) |
DK (2) | DK1139743T3 (el) |
ES (2) | ES2260959T3 (el) |
PT (2) | PT1634498E (el) |
WO (2) | WO2000035280A1 (el) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
KR20050096922A (ko) | 2002-12-20 | 2005-10-06 | 니코노범 에이비 | 물리적 및 화학적으로 안정된 니코틴 함유 입자물질 |
US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
ES2294480T3 (es) * | 2003-03-14 | 2008-04-01 | Agi Therapeutics Research Limited | Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina. |
DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | BIOSYNCHRONE TRANSDERMAL MEDICINES |
AU2006331790A1 (en) * | 2005-12-19 | 2007-07-05 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses therof |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
JP2010505960A (ja) * | 2006-10-09 | 2010-02-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ニコチン禁断症状および/またはタバコ使用の軽減用組成物 |
US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
GB2448224B (en) * | 2007-04-02 | 2010-09-01 | Parkinson S Inst | Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent |
US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
JP2012533547A (ja) * | 2009-07-14 | 2012-12-27 | ターガセプト,インコーポレイテッド | 治療のためのエキソ−s−メカミラミンの方法、使用、及び化合物 |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
PL2576496T3 (pl) | 2010-05-27 | 2017-08-31 | Catalyst Biosciences, Inc. | Niekompetycyjni antagoniści receptorów nikotynowych |
AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
EP2672847B1 (de) | 2011-02-11 | 2015-04-22 | Batmark Limited | Inhalatorkomponente |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
KR101870335B1 (ko) | 2011-09-06 | 2018-07-20 | 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 | 가열식 끽연 가능 물질 |
PL2753202T3 (pl) | 2011-09-06 | 2016-11-30 | Podgrzewanie materiału przeznaczonego do palenia | |
AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
US10080726B2 (en) | 2014-08-22 | 2018-09-25 | Atacama Therapeutics, Inc. | Method for treating hyperhidrosis with dexmecamylamine |
GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
CA3022340C (en) | 2016-04-27 | 2021-09-21 | Nicoventures Holdings Limited | Electronic aerosol provision system and vaporizer therefor |
WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
EP0579260A1 (en) * | 1987-07-07 | 1994-01-19 | Beecham Group Plc | Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
- 1999-12-16 EP EP99967401A patent/EP1139743B1/en not_active Expired - Lifetime
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 EP EP05024899A patent/EP1634498B1/en not_active Expired - Lifetime
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Application Discontinuation
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en active IP Right Grant
- 1999-12-16 EP EP99967396A patent/EP1139744A4/en not_active Withdrawn
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69939498D1 (de) | 2008-10-16 |
PT1139743E (pt) | 2006-06-30 |
ATE320711T1 (de) | 2006-04-15 |
JP2014051528A (ja) | 2014-03-20 |
EP1139744A1 (en) | 2001-10-10 |
DE69930552D1 (de) | 2006-05-11 |
ATE406797T1 (de) | 2008-09-15 |
WO2000035279A1 (en) | 2000-06-22 |
EP1634498B1 (en) | 2008-09-03 |
CA2393442A1 (en) | 2000-06-22 |
ES2313187T3 (es) | 2009-03-01 |
WO2000035280A1 (en) | 2000-06-22 |
EP1139743A4 (en) | 2003-01-02 |
EP1139743B1 (en) | 2006-03-22 |
AU2368600A (en) | 2000-07-03 |
JP2002532393A (ja) | 2002-10-02 |
DK1139743T3 (da) | 2006-07-31 |
ES2260959T3 (es) | 2006-11-01 |
CA2393437A1 (en) | 2000-06-22 |
EP1634498A3 (en) | 2006-03-29 |
US20020016370A1 (en) | 2002-02-07 |
CA2393437C (en) | 2009-12-15 |
JP2002532392A (ja) | 2002-10-02 |
JP2011126909A (ja) | 2011-06-30 |
JP2016065108A (ja) | 2016-04-28 |
DE69930552T2 (de) | 2006-11-30 |
EP1139743A1 (en) | 2001-10-10 |
AU2368200A (en) | 2000-07-03 |
EP1139744A4 (en) | 2003-01-02 |
EP1634498A2 (en) | 2006-03-15 |
PT1634498E (pt) | 2008-10-28 |
DK1634498T3 (da) | 2008-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108577T1 (el) | Συνθεση εξω-s-μεκαμυλαμινης | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
DE60006280D1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
WO2002043652A3 (en) | Anti-proliferative drugs | |
MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
Summers et al. | THA—a review of the literature and its use in treatment of five overdose patients | |
JP2002532392A5 (el) | ||
NZ522326A (en) | Adenosine A2A receptor antagonists | |
ATE433959T1 (de) | Analoge von kokain | |
DK1212060T3 (da) | Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom | |
Sun et al. | Management of tetanus: a review of 18 cases | |
NO317485B1 (no) | Fremgangsmate for fremstilling av ZME-018 gelonin immunokonjugat for behandling av melanom | |
ES2187646T3 (es) | Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. | |
NO984564D0 (no) | FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister | |
MXPA04004826A (es) | Antagonista del receptor de quimioquinas y metodos para su uso. | |
BG103512A (en) | Substituted pyramidine compounds and their application | |
Durant et al. | Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey | |
Feinberg et al. | Methadone and schizophrenia. | |
NZ224502A (en) | Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans | |
Booij | The history of neuromuscular blocking agents | |
CA2511664A1 (en) | 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders | |
Messer et al. | Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors | |
Rosen et al. | Use of cocaine to prevent opiate withdrawal. | |
RU2192275C2 (ru) | Способ лечения опийной наркомании |